Want to see NDRA full AI Analyst Report?

ENDRA Life Sciences (NDRA) Earnings Dates, Call Summary & Reports

859 Followers

Earnings Data

Report Date

Aug 17, 2026

TBA (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.84

Last Year’s EPS

-1.71

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2024

Earnings Call Date:Aug 22, 2024|

% Change Since:

Earnings Call Sentiment|Neutral

The earnings call presented several strategic initiatives aimed at improving ENDRA's focus and operational efficiency, alongside positive developments in management, regulatory strategy, and intellectual property. However, financial challenges and stock performance issues remain concerns.

Company Guidance

During the ENDRA Life Sciences Q2 2024 earnings call, significant guidance was provided by the management team, outlining various strategic initiatives. Notably, the company has completed a 1-for-50 reverse stock split aimed at maintaining its NASDAQ listing, though recent high warrant exercise volumes have impacted their stock price adversely. Six key operational changes were introduced, including the enhancement of the management team with the addition of a seasoned CFO and a new Head of Clinical and Regulatory Affairs. The company plans to conduct a statistically-powered multicenter prospective clinical trial, expanding the number of subjects from 20 to 250. The financial update revealed a $7.3 million net raise from a public offering, with operating expenses reduced by 26% on an annual basis. ENDRA's goal is to complete clinical work and submit a de novo application to the FDA by mid-2025, with the current cash runway projected to fund the company into the first half of 2025. The management reiterated their confidence in ENDRA's technology and market potential, highlighting ongoing efforts to formalize a long-term business strategy and improve financial execution.

Enhanced Management Team

ENDRA has strengthened its management team by adding two experienced operators: Richard Jacroux as CFO and Ziad Rouag as Head of Clinical and Regulatory Affairs, both bringing significant expertise in transforming technology companies and navigating regulatory processes.

Strategic Regulatory Changes

The company is implementing a new FDA regulatory strategy, transitioning from retrospective data to a hypothesis-driven, statistically-powered prospective clinical trial, increasing the number of subjects from 20 to about 250 to achieve statistical power.

Significant Reduction in Operating Expenses

ENDRA reduced operating expenses by over $3 million, approximately a 26% reduction on an annualized basis, without impacting key deliverables, such as clinical data collection for FDA submission.

Strong Intellectual Property Portfolio

The patent portfolio now includes 81 issued patents globally, with 5 additional patents issued in Q2 2024, covering thermoacoustic technology and other applications.

Positive FDA Alignment

Positive feedback from an FDA meeting confirmed alignment on product configuration, clinical study design, and regulatory pathway, setting a clear path for the TAEUS liver device.

ENDRA Life Sciences (NDRA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NDRA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 17, 2026	2026 (Q2)	-0.84 / -	-1.71	―	―	―
May 18, 2026	2026 (Q1)	- / -1.09	-1.86	41.40% (+0.77)	―	―
Mar 31, 2026	2025 (Q4)	-1.23 / -1.09	-1.86	41.40% (+0.77)	―	―
Nov 17, 2025	2025 (Q3)	-1.95 / -2.10	-9.54	77.99% (+7.44)	―	―
Jun 30, 2025	2025 (Q2)	-2.27 / -1.71	-140	98.78% (+138.29)	―	―
May 15, 2025	2025 (Q1)	- / -1.86	-455	99.59% (+453.14)	―	―
Mar 31, 2025	2024 (Q4)	-3.91 / -1.86	-455	99.59% (+453.14)	―	―
Nov 15, 2024	2024 (Q3)	-62.30 / -9.54	-700	98.64% (+690.46)	―	―
Aug 22, 2024	2024 (Q2)	-122.50 / -140.00	-752.5	81.40% (+612.50)	―
May 14, 2024	2024 (Q1)	-472.50 / -455.00	-1627.5	72.04% (+1172.50)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NDRA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 18, 2026	$5.05	$5.41	+7.13%
Mar 31, 2026	$4.65	$4.65	0.00%
Nov 17, 2025	$6.20	$6.69	+7.90%
Jun 30, 2025	$3.51	$3.42	-2.56%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ENDRA Life Sciences Inc (NDRA) report earnings?

ENDRA Life Sciences Inc (NDRA) is schdueled to report earning on Aug 17, 2026, TBA (Confirmed).

What is ENDRA Life Sciences Inc (NDRA) earnings time?

ENDRA Life Sciences Inc (NDRA) earnings time is at Aug 17, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NDRA EPS forecast?

NDRA EPS forecast for the fiscal quarter 2026 (Q2) is -0.84.